Aldosterone blockade in patients with acute myocardial infarction

Circulation

Volumn 107, Issue 20, 2003, Pages 2525-2527

  Pitt, Bertram ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Editorials; Myocardial infarction; Ventricles

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE; ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANRENOIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SPIRONOLACTONE;

ACUTE HEART INFARCTION; CORONARY REPERFUSION; DRUG EFFICACY; EDITORIAL; HEART LEFT VENTRICLE FAILURE; HUMAN; MORTALITY; PRIORITY JOURNAL; SUDDEN DEATH; TREATMENT OUTCOME;

ACUTE DISEASE; ALDOSTERONE ANTAGONISTS; CATECHOLAMINES; COLLAGEN; HEART RATE; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; SPIRONOLACTONE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION; VENTRICULAR REMODELING;

EID: 0038012792     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000072746.11078.36     Document Type: Editorial

References (21)

1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
2. Pitt B, Remme WJ, Zannad F, et al. Eplerenone, a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
3. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents postinfarct left ventricular remodeling associated with suppression of a marker of myocardial cologne synthesis in patients with first anterior acute myocardial infarction. Circulation. 2003;107:2559-2565.
4. Rodriguez JA, Godoy I, Castro P, et al. Ramipril vs. espironolactona en el remodelamiento ventricular izquiredo post-infarcto: randomizado y dobleciego. Rev Med Chile. 1997;125:643-652.
5. Suzuki G, Morita H, Mishima T, et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation. 2002;106:2967-2972.
6. Cicoira M, Zanolla L, Rossi A, et al. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol. 2002;40:304-310.
7. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
8. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation. 2000;102:2700-2706.
9. Weber KT, Sun Y, Campbell SE, et al. Chronic mineralocorticoid excess and cardiovascular remodeling. Steroids. 1995;60:125-132.
10. Hayashi M, Tsutamoto T, Wada A, et al. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol. 2001;38:1375-1382.
11. Modena MG, Aventa P, Menozzi M, et al. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J. 2001;141:41-46.
12. Wang D, Liu Y-H, Yang X-P, et al. Role of selective aldosterone blocker in mice with chronic heart failure following myocardial infarction. Hypertension. 2002;40:412. Abstract.
13. Delyani JA, Robinson EL, Rudolph AE. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol. 2001;281:H647-H654.
14. Guideri G. Death in ventricular fibrillation induced by isoproterenol in doca-salt pretreated rats preceded by changes in myocardial electrolytes. Life Sci. 1983;33:1353-1362.
15. Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1995;76:1259-1265.
16. Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol. 2001;37:1800-1807.
17. Zhang ZH, Francis J, Weiss RM, et al. The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure. Am J Physiol Heart Circ Physiol. 2002;283:H423-H433.
18. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res. 1997;35:30-34.
19. Korkmaz ME, Muderrisoglu H, Ulucam M, et al. Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure. Am J Cardiol. 2000;86:649-653.
20. Chowdhary S, Vaile JC, Fletcher J, et al. Nitric oxide and cardiac autonomic control in humans. Hypertension. 2000;36:264-269.
21. Ward MR, Kanellakis P, Ramsey D, et al. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation. 2001;104:467-472.